The ICASA 2017 theme was ‘Africa: Ending AIDS-delivering differently’ and aimed to engage the whole continent and all stakeholders in the post sustainable development goal (SDG) framework, especially in relation to reaching the UNAIDS target of 90-90-90.
DNDi participated at the event.
The role of point-of-care testing for early infant diagnosis and improved treatment options towards ending paediatric AIDS
Date: Friday, December 8, 2017
With the increased availability of robust point-of-care (POC) molecular technologies for early infant diagnosis (EID), ministries of health (MOHs), along with partners, have begun to scale-up routine POC testing in HIV programs to optimize laboratory networks and improve clinical outcomes. In addition, improved formulations of World Health Organization-recommended treatments are being introduced or are in the final stages of drug development. This session will present how new POC technologies are being scaled up within the diagnostic networks of select countries, as well as highlight new treatment options available for infants and young children, within the broader context of ending pediatric AIDS. Representatives from early adopter countries will share their perspectives on what is needed for a successful and sustainable path to scaling up POC technologies and new optimal pediatric treatments.
- Satellite Event Programme
- Part 2: Towards improved pediatric formulations
Children and adolescents
Date: Saturday, December 9, 2017
Chair: Denis Tindyebwa, Executive Director, The African Network for Care of Children Affected by HIV/AIDS (ANECCA), Uganda
|Prospective Study of Lopinavir Based ART for HIV-infected Children Globally (LIVING Study): Interim 48-week Effectiveness and Safety Results|
Salami O*, Kekitiinwa A, Wamalwa D, Obimbo E, Musiime V, Waweru M, Ouattara G, Odhiambo S, Kyomuhendo F, Simon F, Lee J, Omollo R, Egondi T, Stallaert J.F, Oyaro P, Bukusi E, Mwanga J, Wasunna M, Andrieux-Meyer I, Lallemant M
Date: Wednesday, December 6, 2017
|Assessing acceptance and acceptability of an innovative pediatric antiretroviral lopinavir/ritonavir pellet formulation|
Onyango-Ouma W, Nöstlinger C, Marchal B, Nyamongo I, Salami O, Lallemant M, Nebot Giralt A, Lee J
* Presenting author